Smoking and Outcomes Following Guided De-escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: A Substudy from the Randomized TROPICAL-ACS Trial

Abstract

Prior analyses disclosed variations in antiplatelet drug response and clinical outcomes between smokers and non-smokers, thus the safety and efficacy of any dual antiplatelet therapy (DAPT) de-escalation strategy may differ in relation to smoking status. Hence, we assessed the impact of smoking on clinical outcomes and ADP-induced platelet aggregation following guided de-escalation of DAPT in invasively managed ACS patients.